

[Oxamniquine](#)

Essential medicine status

Section:

[6. Anti-infective medicines 6.1. Anthelmintics 6.1.3. Antischistosomes and other antitrematode medicines](#)

ATC codes: [P02BA02](#)

EMLc

Indication

Schistosomiasis due to *Schistosoma mansoni* ICD11 code: [1G55.1](#)

INN

Oxamniquine

Medicine type

Chemical agent

List type

Complementary

Additional notes

oxamniquine is listed for use when praziquantel treatment fails.

Formulations

Oral > Liquid: 250 mg per 5 mL

Oral > Solid > capsule: 250 mg

EML status history

First added in 1977 ([TRS 615](#))

Changed in 1979 ([TRS 641](#))

Changed in 1997 ([TRS 882](#))

Changed in 2005 ([TRS 933](#))

Changed in 2007 ([TRS 950](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Oxamniquine](#)

DrugBank

[Oxamniquine](#)

Summary of evidence and Expert Committee recommendations

Oxamniquine is recognized as second-line treatment for the treatment of schistosomiasis [praziquantel remains the first-line choice for all forms of schistosomiasis]. Noting that there are significant research gaps for medicines for children in this area, the EMLc Subcommittee decided to endorse this product as essential but highlighted the need for adequate studies to determine the effectiveness and safety of it in children.